Introduction
Thrombin, generated at the site of vascular damage by extrinsic and intrinsic coagulation cascades, is an important agonist for platelet activation. Thrombin mediates its cellular effects primarily through a family of G-protein-coupled protease-activated receptors (PARs). It is known that PARs couple to G q and G 12/13 pathways, 1 and we have demonstrated that thrombin and thrombin receptor-activating peptides cause G i stimulation through P2Y 12 receptor activation by secreted ADP. 2 It has been shown that stimulation of platelets with thrombin results in Akt activation, and P2Y 12 ADP receptor is responsible for a significant proportion of Akt activation. 3 Protein kinase B (PKB; also known as Akt) is a 57-kDa serine/threonine kinase 4 that contains a pleckstrin homology (PH) domain adjacent to a centrally located catalytic domain that is connected to a short C-terminal tail. 5 The catalytic domain of Akt contains a Thr 308 phosphorylation site and a regulatory domain located in the C-terminal tail contains a Ser 473 phosphorylation site. 5 There are at least 3 different Akt isoforms identified in humans, which display more than 80% sequence homology and are named Akt1 (PKB␣), Akt2 (PKB␤), and Akt3 (PKB␥). 6 It has been shown that the major Akt subtype in human platelets is Akt1 rather than Akt2. 7 The Akt1 phosphorylation sites are Thr 308 /Ser, 473 and both translocation of Akt to cell membranes and phosphorylation of both Thr 308 and Ser 473 are required for full enzyme activity. Phosphatidylinositol (PI) 3-kinase has been shown to be implicated in fibrinogen receptor activation, 8 and Akt functions as one of several downstream effectors of PI 3-kinase. 9 ,10 PI 3-kinase products PtdIns 3,4 P 2 and PtdIns 3,4,5 P 3 trigger the simultaneous phosphorylation of Akt by phosphatidylinositol-dependent kinase 1 (PDK1) and 2. Membrane attachment of Akt is a prerequisite for phosphorylation by PDK1 and PDK2, and PDK1 has been shown to phosphorylate Thr 308 of Akt1 and the phosphorylation of Ser 473 is independent of Thr 308 . 11 ADP-induced platelet aggregation requires coactivation of both the P2Y 1 and P2Y 12 receptors that couple to G q and G i , respectively, and concomitant signaling from G q and G i is sufficient and necessary for ADP-induced platelet aggregation. [12] [13] [14] Epinephrine binds to the ␣2A-adrenergic receptor and causes activation of the G z pathway that leads to the pertussis toxin-insensitive inhibition of adenylyl cyclase. 15, 16 It has been shown that activated thrombin receptors in platelets couple to G 12/13 pathways, 1 which are involved in p160 ROCK activation and the subsequent shape change. 17, 18 Y-27632, a specific inhibitor of the Rho-associated protein kinase p160 ROCK , 19 blocks G 12/13 -induced platelet shape change that is independent of an increase of intracellular calcium, indicating that p160 ROCK plays a central role downstream of G 12/13 for mediating shape change. 20 Data from our own studies and others show that Akt is activated by various agonists including ADP, epinephrine, thrombin, and thrombin receptor-activating peptides. 3, 7, 21 It has been shown that Akt phosphorylation stimulated by ADP was preserved in the platelets from G q knockout mice, whereas thrombin-induced Akt phosphorylation was abolished. 3, 22 However, it is controversial whether thrombin-induced Akt phosphorylation is dependent on G q or G i signaling pathways. Woulfe et al 22 reported that the activation of Akt by thrombin occurs in a G q -dependent manner in which secreted ADP can only amplify Akt activation. We have suggested that thrombin-mediated Akt phosphorylation is largely dependent on G i stimulation through P2Y 12 receptor activation by secreted ADP. Even though thrombin-induced Akt phosphorylation depends on secretion, Akt phosphorylation mediated by ADP and epinephrine is much weaker than that caused by thrombin. These findings raised the possibility that there is a potentiating contribution of other G-protein signaling to Akt phosphorylation mediated by G i or G z signaling pathways. The relative contribution of G q or G 12/13 pathways to Akt phosphorylation and the downstream signaling events from G 12/13 activation have not been fully understood. Therefore, we sought to define the contribution of G q or G 12/13 pathways to Akt phosphorylation mediated by G i /G z pathways in platelets.
In this study, we show that selective activation of G 12/13 alone is not sufficient to cause Akt phosphorylation in platelets, but activation of G 12/13 in combination with selective activation of G i /G z signaling in the absence of G q can restore the Akt phosphorylation to the level achieved by PAR agonists in normal platelets, thus indicating the essential role of G 12/13 pathways in potentiation of Akt phosphorylation downstream of PAR receptor activation. There has been an unresolved question of whether coupling of PAR1 to G i is direct or indirect. 23 We have previously demonstrated that PAR1 activation does not lead to G i stimulation in platelets using cAMP levels as an assay. 2 In this study, we confirm this important finding using Akt phosphorylation as the readout. The results also show that G q -dependent pathways do not have any direct effect on PAR-mediated Akt phosphorylation and confirm our previous study that thrombin requires secreted ADP to induce Akt phosphorylation. We also show for the first time that G 12/13 activation downstream of PARs leads to Src family kinase activation, and G 12/13 might mediate its potentiating effect on Akt phosphorylation through Src family kinase.
Materials and methods
Approval for this study was obtained from the Institutional Review Board of Temple University (Philadelphia, PA). Informed consent was provided according to the Declaration of Helsinki.
Materials
Thrombin, 2-MeSADP, epinephrine, MRS-2179, apyrase (type V), and bovine serum albumin (fraction V) were purchased from Sigma (St Louis, MO). YFLLRNP was custom synthesized by New England Biolabs (Beverly, MA), and SFLLRN and AYPGKF were custom synthesized by Invitrogen (Carlsbad, CA). Anti-phospho-Akt (Ser 473 and Thr 308 ) and anti-phospho-Src (Tyr 416 ) antibodies were purchased from Cell Signaling Technology (Beverly, MA). Alkaline phosphatase (AP)-labeled secondary antibody was from Kirkegaard & Perry Laboratories (Gaithersburg, MD). CDP-Star chemiluminescent substrates were purchased from Applied Biosystems (Foster City, CA). Y-27632, LY294002, and PP2 (4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazole [3,4-D] pyrimidine) were purchased from Biomol Research Laboratories (Plymouth Meeting, PA). PP3 (4-amino-7-phenylpyrazol[3,4-D]pyrimidine) was purchased from Calbiochem (San Diego, CA). AR-C69931MX was a gift from AstraZeneca (Loughborough, United Kingdom). YM-254890 was a generous gift from Yamanouchi Pharmaceutical (Ibaraki, Japan). All other reagents were reagent grade, and deionized water was used throughout.
Animals
G␣ q -deficient mice were obtained from T. Kent Gartner, 24 with permission from Stefan Offermanns (University of Heidelberg, Heidelberg, Germany).
Preparation of human platelets
Whole blood was obtained from a pool of healthy volunteers in a one-sixth volume of ACD (2.5 g sodium citrate, 1.5 g citric acid, and 2.0 g glucose in 100 mL of H 2 O). Platelet-rich plasma (PRP) was prepared by centrifugation of citrated blood at 230 rcf (g) for 20 minutes at room temperature (RT). Acetylsalicylic acid was added to PRP to a final concentration of 1 mM, and the preparation was incubated for 45 minutes at 37°C followed by centrifugation at 980 rcf (g) for 10 minutes at RT. The platelet pellet was resuspended in Tyrode buffer (138 mM NaCl; 2.7 mM KCl; 2 mM MgCl 2 ; 0.42 mM NaH 2 PO 4 ; 5 mM glucose; 10 mM HEPES, pH 7.4; and 0.2% bovine serum albumin) containing 0.05 unit/mL apyrase. This low concentration of apyrase is not enough to block responses to ADP but will prolong the responsiveness of platelets to ADP by preventing desensitization of the P2Y receptors. These conditions have been standardized in the laboratory. The platelet count was adjusted to 2 ϫ 10 8 cells/mL.
Preparation of mouse platelets
Blood was collected from the vena cava of anesthetized mice into syringes containing one-tenth blood volume of 3.8% sodium citrate as anticoagulant. Red blood cells were removed by centrifugation at 100 rcf (g) for 10 minutes at RT. PRP was recovered and platelets were pelleted at 400 rcf (g) for 10 minutes at RT. The platelet pellet was resuspended in Tyrode buffer (pH 7.4) containing 0.05 unit/mL apyrase.
Western blotting
Platelets were stimulated with agonists under nonstirring conditions for the appropriate time, and the reaction was stopped by the addition of 3 ϫ sodium dodecyl sulfate (SDS) sample buffer. In some experiments, Y-27632 (10 M), a p160 ROCK inhibitor, and PP2 (10 M), a Src family kinase inhibitor, were added and incubated for 5 minutes at 37°C without stirring before agonist stimulation. Levels of phospho-Akt and phospho-Src were determined after immunoblotting with anti-phospho-Akt (Ser 473 and Thr 308 ) and anti-phospho-Src (Tyr 416 ) antibodies. Platelet samples were boiled for 5 minutes and proteins were separated on 10% SDSpolyacrylamide gel electrophoresis (PAGE) and transferred onto polyvinylidene difluoride membrane. Nonspecific binding sites were blocked by incubation in Tris-buffered saline/Tween (TBST; 20 mM Tris, 140 mM NaCL, 0.1% [v/v] Tween 20) containing 0.5% (w/v) milk protein and 3% (w/v) bovine serum albumin (BSA) for 30 minutes at RT, and membranes were incubated overnight at 4°C with primary antibody (1:1000 in TBST/2% BSA) with gentle agitation. After 3 washes for 5 minutes each with TBST, the membranes were probed with AP-labeled goat anti-rabbit IgG (1:5000 in TBST/2% BSA) for 1 hour at RT. After additional washing steps, membranes were then incubated with CDP-Star chemiluminescent substrates for 10 minutes at RT and immunoreactivity was detected using Fujifilm Luminescent Image Analyzer (model LAS-3000 CH; Tokyo, Japan).
Human platelet aggregation
Agonist-induced platelet aggregation was measured using a lumiaggregometer (Chrono-Log, Havertown, PA) at 37°C with stirring (900 rpm). A 0.5-mL sample of aspirin-treated washed platelets was stimulated with agonist, and change in light transmission was measured. Agonists were added simultaneously for platelet stimulation, and platelets were preincubated with 10 M Y-27632 or 50 nM YM-254890 for 5 minutes at 37°C before agonist stimulation in some experiments. Each sample was allowed to aggregate for at least 5 minutes. The chart recorder (Kipp and Zonen, Bohemia, NY) was set for 0.2 mm/s.
Results

Characterization of YFLLRNP-mediated Akt phosphorylation in human platelets
It has been shown that activated thrombin receptors in platelets couple to G 12/13 pathways 1 that are involved in Rho kinase p160 ROCK activation and the subsequent shape change. 17, 18, 25 Low concentrations of YFLLRNP, a heptapeptide binding to PAR1, causes shape change without calcium mobilization in platelets. 26 This shape change is mediated by the activation of G 12/13 pathways without activation of the G q pathways. In human platelets, we used this selective agonist of G 12/13 pathways in combination with selective activation of G i /G z pathways to demonstrate the contribution of G 12/13 signaling to Akt phosphorylation. To determine the kinetics of Akt phosphorylation, Ser 473 phosphorylation was monitored over a time range of 0.5 to 20 minutes. Figure 1A shows that an increase in Ser 473 phosphorylation in response to YFLLRNP (500 M) was detectable within 1 minute of stimulation, and the level of phosphorylation peaked at around 5 minutes of stimulation. We exposed platelets to different concentrations of YFLLRNP ranging from 40 to 500 M, and Ser 473 phosphorylation was measured at 5 minutes after stimulation. Figure 1B illustrates that YFLLRNP induced a concentration-dependent increase in Akt phosphorylation. An increase in Ser 473 phosphorylation was detectable at concentrations above 200 M YFLLRNP, suggesting that higher concentrations of YFLLRNP activate both G q and G 12/13 signaling. However, when human platelets were stimulated with low concentrations of YFLLRNP that activate only the G 12/13 signaling cascade, YFLLRNP failed to cause Akt phosphorylation, suggesting that G 12/13 signaling alone is not capable of causing Akt phosphorylation in human platelets.
Contribution of G 12/13 signaling to Akt phosphorylation in human platelets
Activation of G 12/13 pathways results in platelet shape change that involves Rho kinase. 18, 25 As shown in Figure 2A , YFLLRNPinduced (60 M) platelet shape change was completely inhibited in the presence of 10 M Y-27632, 25 Rho kinase p160 ROCK inhibitor, suggesting that a low dose of YFLLRNP causes selective activation of G 12/13 pathways. Immunoblot analysis revealed that YFLLRNP (60 M) failed to phosphorylate Akt at Ser 473 in human platelets, whereas stimulation of the G i -coupled P2Y 12 receptor or G zcoupled ␣ 2A -adrenergic receptor by 2-MeSADP and epinephrine, respectively, were able to cause Akt phosphorylation ( Figure 2B ). However, YFLLRNP-mediated G 12/13 signaling in combination with G i /G z signaling caused a 1.92-to 2.37-fold increase in Akt phosphorylation compared with those obtained with epinephrine or 2-MeSADP alone ( Figure 2B ). These results suggest that G 12/13 signaling has a potentiating effect on Akt phosphorylation when combined with selective G i or G z signaling in human platelets.
Effect of Rho kinase in G 12/13 -and G i /G z -mediated Akt phosphorylation
It has been shown that G 12/13 -mediated platelet shape change is inhibited by the p160 ROCK inhibitor Y-27632 and is independent of PLC/Ca 2ϩ /calmodulin myosin light-chain kinase signaling. 18, 20 Thus, it is suggested that Rho kinase p160 ROCK is a key signaling molecule downstream of G 12/13 pathways, and we investigated its role in the potentiation of Akt phosphorylation. Since G 12/13 -induced platelet shape change was blocked by the Rho kinase inhibitor Y-27632, we tested the effect of Y-27632 on Akt phosphorylation induced by G 12/13 and G i /G z pathways. Figure 3 shows that Y-27632 has no effect on Akt phosphorylation induced by costimulation of G 12/13 and G i /G z signaling, indicating that Rho/Rho kinase does not have any role in potentiation of Akt 
However, AR-C69931MX, an antagonist at the G i -coupled P2Y 12 receptor, inhibited concomitant G 12/13 -and G i -mediated Akt phosphorylation. This result was substantiated in experiments where epinephrine reversed the inhibitory effect of AR-C69931MX on Akt phosphorylation. PI 3-kinase has been shown to be a key signaling molecule for Akt phosphorylation. 9 LY294002, a PI 3-kinase inhibitor, 27 blocked Akt phosphorylation caused by costimulation of G 12/13 and G i /G z signaling, suggesting the important role of PI 3-kinase in this Akt phosphorylation. It appears that PI 3-kinase mediates its effect through the P2Y 12 -or ␣ 2A -adrenergic-stimulated G i /G z signaling pathways.
Contribution of G 12/13 signaling to Akt phosphorylation in mouse platelets
We compared Akt phosphorylation in response to AYPGKF, a PAR4-activating peptide, and thrombin in platelets from wild-type mice as well as from mice lacking G␣ q . Immunoblot analysis revealed that AYPGKF and thrombin failed to phosphorylate Akt at Ser 473 and Thr 308 in platelets from G␣ q knockout mice ( Figure 4A ). However, AYPGKF and thrombin caused phosphorylation of Ser 473 and Thr 308 in wild-type littermates, which was partially inhibited in the presence of AR-C69931MX. We have shown that thrombin receptors fail to directly couple to G i in platelets and depend on secreted ADP for G i stimulation 2 and that thrombin-induced Akt phosphorylation depends on G i pathways. 3 Therefore, our data suggest the possible contribution of other G-protein-coupled signaling to Akt phosphorylation mediated by thrombin in platelets.
It has been shown that thrombin receptors couple to G q and G 12/13 pathways. 1 To determine the contribution of G 12/13 pathways to Akt phosphorylation in mouse platelets, we selectively supplemented G i or G z stimulation to AYPGKF-and thrombin-induced Akt phosphorylation in G␣ q -deficient mouse platelets. Figure 4B illustrates that the activation of PAR receptors with thrombin and AYPGKF in G␣ q -deficient platelets, which couple to G 12/13 pathways, did not induce Akt phosphorylation. Simultaneous addition of either 2-MeSADP or epinephrine to thrombin-or AYPGKF-stimulated G␣ q -deficient platelets resulted in a significant increase (3.2-to 4.5-fold) in Akt phosphorylation compared with that induced by 2-MeSADP or epinephrine alone. These results suggest that G 12/13 signaling from thrombin receptors is capable of potentiating Akt phosphorylation mediated by G i or G z pathways in mouse platelets.
To confirm the contribution of G 12/13 signaling to potentiation of Akt phosphorylation, we exposed G␣ q -deficient platelets to different concentrations of AYPGKF in the presence of 2-MeSADP. Figure 4C shows that selective activation of G 12/13 signaling by AYPGKF induced a concentration-dependent increase in Akt phosphorylation mediated by 2-MeSADP-induced G i stimulation, confirming the role of G 12/13 signaling in potentiation of Akt phosphorylation when combined with G i signaling. Taken together with our data showing that potentiation of Akt phosphorylation induced by AYPGKF and thrombin in G␣ q -deficient platelets was much stronger than that induced by a low dose of YFLLRNP in human platelets, these results suggest that AY-PGKF and thrombin in combination with G i /G z in G␣ q -deficient platelets induced more robust Akt phosphorylation through strong stimulation of G 12/13 pathways.
Contribution of G q versus G 12/13 pathways to Akt phosphorylation
YM-254890, which is isolated from culture broth of Chromobacterium species, has been shown to inhibit ADP-induced platelet aggregation by selectively inhibiting G q activation. 28 In order to compare the relative contribution of G q and G 12/13 pathways, we compared Akt phosphorylation in the presence and absence of the G q -selective inhibitor YM-254890.
To ensure that YM-254890 inhibits the G q pathway specifically, we measured agonist-induced platelet aggregation in the presence and absence of 50 nM YM-254890. YM-254890 or MRS-2179, a G q -coupled P2Y1 receptor antagonist, 29 blocked 2-MeSADPinduced platelet shape change and aggregation ( Figure 5A ). However, YM-254890 did not block the 2-MeSADP-induced inhibition of cAMP levels in platelets (data not shown). AYPGKF, which couples to G q and G 12/13 pathways, caused platelet shape change in the presence of YM-254890. This shape change was abolished by the addition of Rho kinase inhibitor Y-27632, which has been shown to block G 12/13 -induced shape change ( Figure 5A ). These data indicate that YM-254890 selectively inhibits G q signaling in platelets.
It has been shown that ADP depends on stimulation of G i , but not G q , to activate Akt. 3, 22 Immunoblot analysis revealed that 2-MeSADP caused Akt phosphorylation in the presence and absence of MRS-2179 or YM-254890, whereas 2-MeSADPinduced Akt phosphorylation was abolished by AR-C69931MX ( Figure 5B ), confirming that YM-254890 is a G q -selective inhibitor and does not have a nonselective effect on Akt phosphorylation. In order to verify the relative contribution of G q and G 12/13 pathways to PAR-induced Akt phosphorylation, we investigated the effect of combined activation of G 12/13 and G i /G z signaling in the presence of YM-254890. As shown in Figure 5C , SFLLRN-, AYPGKF-, and thrombin-induced Akt phosphorylation was abolished in the presence of YM-254890, confirming our previous study that PAR receptors cannot directly couple to G i signaling. 2 However, supplemental G i or G z signaling by 2-MeSADP or epinephrine in the presence of YM-254890 restored Akt phosphorylation to the extent achieved by these agonists. These results provide further evidence that G q signaling does not have any direct effect on Akt phosphorylation and that G 12/13 signaling downstream of PARs is essential to achieve normal extent of Akt phosphorylation by thrombin and thrombin receptor-activating peptides in platelets.
Role of Src family kinase in G 12/13 -and G i /G z -mediated Akt phosphorylation
As the Rho kinase inhibitor Y-27632 did not block Akt phosphorylation, we suggest that there is a separate pathway downstream of G 12/13 stimulation that contributes to potentiation of Akt phosphorylation. Immunoblot analysis of the phosphorylation of Src tyrosine 416, which correlates with Src activity, revealed that AYPGKF and thrombin were able to induce an increase in Src phosphorylation in G␣ q -deficient platelets ( Figure 6A) , suggesting that selective G 12/13 activation results in activation of Src family kinase. SFLLRN, AYPGKF, and thrombin were also able to induce an increase in Src phosphorylation in the presence of 50 nM YM-254890 in human platelets (data not shown). Y-27632 had no effect on G 12/13 -induced Src phosphorylation, which was blocked by a selective inhibitor of Src family tyrosine kinase PP2, 30 indicating that Rho kinase does not have any role in G 12/13 -induced Src phosphorylation. To determine the role of Src kinase in Akt phosphorylation, we measured the effects of PP2 on Akt phosphorylation induced by combined G 12/13 and G i /G z stimulation. As Figure 6B , Akt phosphorylation induced by simultaneous addition of either 2-MeSADP or epinephrine to thrombin or AYPGKF in G␣ q -deficient platelets was abolished in the presence of PP2. This suggests that a Src-dependent pathway in the G 12/13 signaling pathway plays an important role in this potentiation of Akt phosphorylation in the presence of G i /G z signaling in platelets.
Recently, we have suggested that both G i and G z signaling can cause Src activation in platelets. 31 In order to verify the role of Src in Akt phosphorylation mediated by G i /G z stimulation, we tested the effect of PP2 and PP3, a control compound that does not inhibit tyrosine kinase activity, on Akt phosphorylation induced by G i or G z alone. Whereas PP2 abolished Akt phosphorylation induced by G i and G z signaling, the control compound PP3 had no effect ( Figure 6C ), indicating that Src activity plays a role in Akt phosphorylation mediated by selective G i or G z signaling.
Discussion
It has been shown that Akt is activated by various agonists including ADP, epinephrine, and thrombin in platelets. 3, 7, 21, 22 We have shown that ADP causes Akt phosphorylation independently of G q stimulation, that thrombin-and thrombin receptor-activating peptide-induced Akt phosphorylation depends predominantly on G i stimulation through P2Y 12 receptor activation by secreted ADP, and that epinephrine substitutes for the P2Y 12 receptor-mediated effects through G z signaling cascade. 3 However, the activation of P2Y 12 or ␣ 2A -adrenergic receptors with 2-MeSADP and epinephrine, which couple to G i and G z , respectively, induces a much smaller extent of Akt phosphorylation than thrombin or thrombin receptor-activating peptides in platelets. Akt phosphorylation in stirred platelets has been shown to be biphasic, first through inside-out signaling and then through outside-in signaling. 32 Thus, when aggregation is allowed to occur, Akt phosphorylation caused by thrombin could be stronger because thrombin can cause platelet aggregation to a greater extent than ADP and hence could cause stronger Akt phosphorylation. However, platelets were prevented from aggregating in our study to eliminate the contribution of outside-in signaling, and yet thrombin causes more Akt phosphorylation than ADP. Hence, it is conceivable that there might be some potentiating contribution of other G-protein signaling to Akt phosphorylation mediated by G i or G z pathways. In particular, we have focused on the potentiating effect of G 12/13 pathways on the Akt phosphorylation mediated by G i /G z pathways.
It has been shown that thrombin receptors couple to G q and G 12/13 pathways. 1 YFLLRNP binds to PAR1 and causes shape change without activating the G q pathways when used at low concentrations, and this shape change is mediated by the G 12/13 pathways. When human platelets are stimulated with a low concentration of YFLLRNP, YFLLRNP fails to cause Akt phosphorylation, suggesting that G 12/13 signaling is unable to induce Akt phosphorylation independently. However, YFLLRNP significantly increases the Akt phosphorylation in combination with selective activation of either G i or G z pathways, suggesting that G 12/13 pathways play an important role in potentiating Akt phosphorylation mediated by G i /G z pathways in human platelets. In addition, AYPGKF and thrombin fail to induce Akt phosphorylation in G␣ q -deficient platelets, confirming that G 12/13 signaling alone does not have any role in Akt phosphorylation in mouse platelets. When we selectively supplemented G i or G z signaling to AYPGKF-and thrombin-induced Akt phosphorylation in G␣ q -deficient platelets, Akt phosphorylation was dramatically potentiated. These results further confirm that G 12/13 signaling has a potentiating contribution to G i /G z -induced Akt phosphorylation in both human and mouse platelets.
Even though G i signaling represents the main signaling pathway leading to Akt phosphorylation, some degree of thrombin-induced Akt phosphorylation has been shown in platelets even in the absence of P2Y 12 receptor activation. Since thrombin receptors directly couple to G q and activate G i by secreted ADP, 2 it has raised the speculation that thrombin can mediate Akt phosphorylation by the G q -dependent pathways that do not require secreted ADP. 22 This may be due to the fact that they did not consider the contribution of G 12/13 signaling to Akt phosphorylation. Platelet granules contain several other agonists, such as chemokines and epinephrine, that could activate G i /G z pathways. Hence, thrombin could activate G i /G z pathways even in the absence of P2Y 12 receptor by these other granule contents. Taken together with our data showing that Akt phosphorylation mediated by G z signaling with epinephrine was potentiated by selective activation of G 12/13 signaling, our study strongly suggests that this partial Akt phosphorylation that is independent of ADP secretion may not be due to the direct effect of G q but to potentiating contribution of G 12/13 signaling to Akt phosphorylation mediated by G z signaling. Our study also reveals that the level of PAR-induced Akt phosphorylation is not affected by the G q -selective inhibitor YM-254890 when G 12/13 is supplemented with G i /G z signaling. These results further confirm that G 12/13 , but not G q , signaling downstream of PARs is essential to achieve a normal extent of Akt phosphorylation. It also confirms that the absence of Akt phosphorylation in the absence of G q signaling is due not to the direct effect of G q on Akt phosphorylation, but to the absence of G i /G z stimulation by secretion.
It is controversial whether coupling of PAR1 to G i is direct or indirect. 23 Several groups have shown that PAR1 activates both G q and G i pathways whereas PAR4 couples to only the G q pathway. [33] [34] [35] If PAR1 can directly couple to G i pathways independently of secretion, PAR1 could activate both G 12/13 and G i pathways in the absence of G q pathways in human platelets. Thus, we expect the normal Akt phosphorylation in response to PAR1 agonist SFLLRN in the absence of G q pathways because coactivation of both G 12/13 and G i pathways leads to normal Akt phosphorylation. In our hands, SFLLRN failed to induce Akt phosphorylation in the presence of YM-254890 ( Figure 5C ), suggesting that PAR1 can Figure 7 . Outline of the signaling events leading to PAR-mediated protein kinase B/Akt activation in platelets. Thrombin and thrombin receptor-activating peptides induce Akt activation in platelets through secreted ADP that stimulates Gi signaling pathways in which Src kinase and PI 3-kinase play an important role. G12/13 signaling potentiates Akt phosphorylation mediated by Gi pathways, and costimulation of G12/13 and Gi signaling can induce the same extent of Akt phosphorylation achieved by PAR agonists in normal platelets. Activation of G12/13 signaling might mediate its potentiating effects through Src kinase activation, and Src kinase plays an important role in ADP-and thrombin-mediated Akt phosphorylation. The mechanism and the specific member of Src family kinases contributing to Akt phosphorylation are not clear. Note that consistent with our previous observations, PAR stimulation in platelets does not lead to direct G i activation. 2 only couple to G 12/13 and not G i pathways in the absence of G q in human platelets. Hence, this study confirms our previous findings 2 and, using a different downstream signaling molecule, clearly demonstrates that PAR1 does not directly stimulate G i pathways in platelets.
It has been shown that the Rho kinase p160 ROCK is an important signaling molecule involved in G 12/13 -induced shape change. 18 Although the p160 ROCK inhibitor Y-27632 can block G 12/13 -mediated platelet shape change, our study reveals that Y-27632 fails to inhibit Akt phosphorylation caused by concomitant G 12/13 and G i /G z signaling, suggesting that the Rho A/Rho kinase (p160 ROCK )-dependent signaling cascade does not play any significant role in potentiating Akt phosphorylation although most G 12/13 to date has involved the Rho A/Rho kinase (p160 ROCK )-dependent pathway. Furthermore, it suggests that there is a separate pathway downstream of G 12/13 contributing to potentiation of Akt phosphorylation that is independent of the Rho A/Rho kinase pathway.
Src family tyrosine kinases participate in the signal transduction pathways of various hematopoietic cells. 36 Six of 8 members of Src family kinases are present in platelets. 37 It has been shown that the Src family kinases Lyn and Fyn play a role in glycoprotein VI-mediated platelet activation. 38 It has also been described that stimulation of G-protein-coupled receptors induces activation of Src kinases. 39 However, the functional roles of Src family kinases in platelet activation have not been well defined. We show here that thrombin receptor-mediated activation of G 12/13 leads to tyrosine phosphorylation of Src family kinase in platelets, suggesting that Src kinase is an important downstream molecule of G 12/13 signaling. Consistent with our observations, it has been shown that constitutively active G␣ 12 -expressing MDCK (Madin-Darby canine kidney) cells have an increased Src tyrosine kinase activity. 40 It is also shown that G␣ 13 stimulates Src kinase activity in Rat-1 fibroblasts, suggesting the involvement of a Src-dependent pathway in G␣ 13 -mediated cell proliferation and transformation. 41 We then measured the effect of the Src kinase inhibitor PP2 on concomitant G 12/13 -and G i /G z -mediated Akt phosphorylation in G␣ q -deficient platelets and found that PP2 blocked Akt phosphorylation induced by selective activation of either G i or G z signaling in the presence of G 12/13 pathways. It has recently been reported that Src kinase is activated primarily by the G q -coupled P2Y 1 receptor in platelets, 42 but G q -mediated Src activation may not have any contribution to Akt phosphorylation since G q signaling does not have any role in Akt phosphorylation in platelets. Our previous work has shown that both G i and G z signaling can cause Src activation, 31 and we have found that the Src kinase inhibitor PP2 inhibits G i /G z -mediated Akt phosphorylation. Thus, our study demonstrates that Src kinase downstream of G i and G 12/13 , but not G q , is a key signaling molecule in the thrombin-mediated Akt phosphorylation, and G 12/13 signaling cascade might mediate its potentiating effect on Akt phosphorylation through Src-dependent pathways ( Figure 7 ). Further studies are required to identify which member of Src family kinases plays a role in this Akt phosphorylation.
In conclusion, we demonstrate that G 12/13 , but not G q , signaling downstream of PARs is essential to achieve normal Akt phosphorylation by thrombin and thrombin receptor-activating peptides in platelets. While G q signaling does not have a direct effect on Akt phosphorylation, it contributes to G i stimulation by secreted ADP that is also required for thrombin-induced Akt phosphorylation. Furthermore, Src family kinases are essential for ADP-and thrombin-induced Akt phosphorylation in platelets.
